Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep;9(9):103725.
doi: 10.1016/j.esmoop.2024.103725. Epub 2024 Sep 5.

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria

A B Apolo  1 , J Bellmunt  2 , L Cordes  1 , S Gupta  3 , T Powles  4 , J E Rosenberg  5 , M S Van Der Heijden  6
Affiliations

The clinical use of enfortumab vedotin and pembrolizumab in patients with advanced urothelial carcinoma: using clinical judgement over treatment criteria

A B Apolo et al. ESMO Open. 2024 Sep.
No abstract available

PubMed Disclaimer

References

    1. Powles T., Valderrama B.P., Gupta S., et al. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024;390(10):875–888. - PubMed
    1. Powles T., Bellmunt J., Comperat E., et al. ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma. Ann Oncol. 2024;35(6):485–490. - PubMed
    1. Flaig T.W., Spiess P.E., Abern M., et al. NCCN Guidelines Insights: Bladder Cancer, Version 3.2024. J Natl Compr Canc Netw. 2024;22(4):216–225. - PubMed
    1. Galsky M.D., Hahn N.M., Rosenberg J., et al. Treatment of patients with metastatic urothelial cancer “unfit” for Cisplatin-based chemotherapy. J Clin Oncol. 2011;29(17):2432–2438. - PubMed
    1. Bellmunt J., de Wit R., Vaughn D.J., et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med. 2017;376(11):1015–1026. - PMC - PubMed

MeSH terms

Substances

LinkOut - more resources